Aardvark Therapeutics has appointed David Zhang, Ph.D., MBA, as an independent director on its Board. Zhang brings over 25 years of experience in clinical strategy, biostatistics, and regulatory submissions from leading biotech firms. His expertise is expected to support Aardvark's development and regulatory efforts for ARD-101, a treatment for Prader-Willi Syndrome. This appointment comes at a critical time as the company navigates regulatory pathways and plans future clinical development.
Aardvark Therapeutics' recent board appointment comes amid a health sector where 29 of 128 US stocks rose and 91 fell on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 08, 2026 18:43 WIB: ROIV (Roivant Sciences Ltd.) traded at USD 34.75 with a 1-day change of -2.20%, RXRX (Recursion Pharmaceuticals Inc) at USD 4.18 with a 1-day change of -2.11% and a typical hold time of 22 days, and ABEO (Abeona Therapeutics Inc) at USD 5.18 with a 1-day change of +1.97% and 100% buy order activity.
MIND, an AI-native data loss prevention (DLP) platform, was named "Data Loss Prevention Platform of the Year" in the 2026 CyberSecurity Breakthrough Awards. The platform uses advanced AI to discover, detect, and prevent sensitive data leaks across va...
The global Mivan construction market is projected to grow from $3.92 billion in 2025 to $7.05 billion by 2031, at a CAGR of 10.28%. Growth is fueled by demand for rapid mass housing, affordable residential projects, and faster construction enabled by...
RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, suppo...
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
UnitedHealth Group is expected to report Q3 earnings of $4.12 per share on $111.3 billion revenue, with investors closely watching medical cost trends and Medicare Advantage membership. The company improved its medical care ratio and operating earnin...
